Technical analyst Hitesh Chotalia has maintained 'buy' rating on Sun Pharmaceutical Industries Ltd stock with a target of Rs 468.

According to analyst, the investors can buy the stock with a stop loss of Rs 445.

Today, the stock of the company opened at Rs 454.80 on the Bombay Stock Exchange (BSE).

The share price has seen a 52-week high of Rs 476 and a low of Rs 284 on BSE.

Current EPS & P/E ratio stood at 17.39 and 26.07 respectively.

Sun Pharmaceutical Industries has got a tentative nod from US health watchdog to sell generic donepezil hydrochloride tabs utilized for the treatment of Alzheimer's disease in the US market.

The tentative authorization has been forwarded by USFDA for its ANDA to sell the medicine in the potencies of 5 mg and 10 mg.

"Annual sale in US for these strengths is approximately USD 2.5 billion," the company stated.

Donepezil hydrochloride tabs are generic edition of Eisai's Aricept pills used for trating Alzheimer's disease.

On Nov 18, Sun Pharma said that USFDA has offered its division a sanction for its ANDA to sell a generic edition of once-a-day Tiazac extended release capsules.